In the present case, the elevated expression of RBFOX3 in TME-ARPCs and the depletion of RBFOX3 in TME-de novo NEPCs may reflect the tumor progression potential of de novo NEPCs [26]. The gene discussed is RBFOX3; the disease is neoplasm.